Sanofi and Regeneron are prioritizing pediatric care, particularly in their recent progress with the potent anti-inflammatory drug, Dupixent. On January 25, 2024, the FDA approved Dupixent, an IL-4 receptor alpha antagonist, for the treatment of eosinophilic esophagitis (EoE) in children aged 1 to 11, weighing at least 33 pounds. This marks Dupixent as the inaugural treatment in the United States for youngsters within this age range who are affected by the disorder.
This approval broadens the original FDA approval granted in May 2022 for EoE in individuals aged 12 years and above, with a minimum weight of 40 kg. Dupixent underwent Priority Review by the FDA for thi...
